low - Clinical trial timelines and drug development activities are largely insulated from GDP fluctuations. Royalty revenue from Mavyret shows minimal cyclicality as HCV treatment is medically necessary. However, partnership deal flow and biotech M&A activity can slow during recessions as large pharma becomes more conservative with capital allocation. Patient enrollment in trials may see modest delays during severe economic stress.

Rising interest rates negatively impact valuation multiples for pre-revenue biotech stocks as discount rates increase for future cash flows (which may be 5-10+ years out). Higher rates also increase opportunity cost of holding cash-burning equities vs risk-free alternatives. Conversely, Enanta's $130M+ cash balance generates higher interest income in rising rate environments, partially offsetting burn rate. Financing costs for potential debt raises increase, though company currently maintains low leverage (0.45x D/E).

growth/speculative - Attracts biotech-focused investors seeking asymmetric risk/reward from clinical catalysts and partnership optionality. Negative earnings and cash flow eliminate value and dividend investors. Recent 88% one-year return and 72% six-month return indicate momentum/event-driven interest around clinical milestones. Institutional ownership likely concentrated among healthcare specialist funds and biotech ETFs rather than broad index funds.